Dataset Information

PD-1 Blockade Aggravates Epstein-Barr Virus⁺ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4⁺ T Cell Dysregulations.

ABSTRACT: Post-transplant lymphoproliferative disorder (PTLD) is one of the most common malignancies after solid organ or allogeneic stem cell transplantation. Most PTLD cases are B cell neoplasias carrying Epstein-Barr virus (EBV). A therapeutic approach is reduction of immunosuppression to allow T cells to develop and combat EBV. If this is not effective, approaches include immunotherapies such as monoclonal antibodies targeting CD20 and adoptive T cells. Immune checkpoint inhibition (ICI) to treat EBV⁺ PTLD was not established clinically due to the risks of organ rejection and graft-versus-host disease. Previously, blockade of the programmed death receptor (PD)-1 by a monoclonal antibody (mAb) during ex vivo infection of mononuclear cells with the EBV/M81⁺ stra

SUBMITTER: Volk V

PROVIDER: S-EPMC7837057 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

PD-1 Blockade Aggravates Epstein-Barr Virus⁺ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4⁺ T Cell Dysregulations.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

PD-1 Blockade Aggravates Epstein-Barr Virus+ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4+ T Cell Dysregulations.

OmicsDI is part of the ELIXIR infrastructure

Tweets

PD-1 Blockade Aggravates Epstein-Barr Virus⁺ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4⁺ T Cell Dysregulations.